- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.11.25 | GSK's Tesaro, AnaptysBio lock horns in court over Jemperli agreement | ||
| 21.11.25 | Semaglutide compounder drops claims after Novo Nordisk challenge | ||
| 20.11.25 | Moderna takes out $1.5B loan, outlines commercial and R&D strategy in bid to break even by 2028 | ||
| 20.11.25 | Sun Pharma shines a light on diabetic retinopathy in SeeBeyondSugar campaign | ||
| 20.11.25 | With 2 FDA nods for Eylea HD, Regeneron is 'no longer fighting Vabysmo with both hands tied behind its back,' analyst says | ||
| 20.11.25 | Pfizer, Tris Pharma ink $41.5M deal to settle ADHD drug fraud allegations in Texas | ||
| 20.11.25 | Indian API maker Cdymax hit with FDA warning letter tied to drug ingredients testing | ||
| 19.11.25 | Bayer edges onto Boehringer's turf with FDA nod for HER2-mutated lung cancer med Hyrnuo | ||
| 19.11.25 | Moderna blueprints $140M plant in bid to bring end-to-end mRNA production to US | ||
| 19.11.25 | Novartis maps out plan for 'flagship' production hub in NC, eyes 700 hires | ||
| 19.11.25 | Agios readies FDA push in sickle cell disease despite mixed ph. 3 results, shares plummet | ||
| 19.11.25 | Celltrion to widen US manufacturing reach with $478M investment at former Lilly plant | ||
| 19.11.25 | After Lundbeck's surprise bid, Alkermes sweetens deal to acquire Avadel | ||
| 18.11.25 | Arrowhead strikes true with 1st FDA approval of genetic disorder drug, but Ionis competition looms | ||
| 18.11.25 | Sackler family, Purdue Pharma's $7.4B settlement plan wins bankruptcy judge's approval | ||
| 18.11.25 | Avadel views Lundbeck's $2.4B buyout offer as 'superior,' kicking the ball back to Alkermes' court | ||
| 18.11.25 | Merck advances Winrevair in subset of heart failure patients | ||
| 18.11.25 | FDA takes issue with AstraZeneca TV ad, citing 'misleading impression' of Farxiga indications | ||
| 18.11.25 | Regeneron pledges $2B to convert former magazine factory into drug plant: NY governor | ||
| 17.11.25 | Cytokinetics steps into Bristol Myers' shoes, funding heart registry ahead of commercial clash | ||
| 17.11.25 | After delay, Sandoz's biosimilar Tyruko launches in US to pressure Biogen's blockbuster MS med Tysabri | ||
| 17.11.25 | Novo unveils newly reduced self-pay prices for Wegovy, Ozempic after White House deal | ||
| 17.11.25 | Trump relents on Swiss tariffs, knocking rate on pharmaceuticals and other goods down to 15% | ||
| 17.11.25 | Jazz's HER2 drug Ziihera chalks up another win with 'practice changing' phase 3 result | ||
| 14.11.25 | FDA restricts Sarepta's gene therapy Elevidys after Duchenne patient deaths |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .